MA49896A - Nouveaux analogues d'insuline acylés et leurs utilisations - Google Patents
Nouveaux analogues d'insuline acylés et leurs utilisationsInfo
- Publication number
- MA49896A MA49896A MA049896A MA49896A MA49896A MA 49896 A MA49896 A MA 49896A MA 049896 A MA049896 A MA 049896A MA 49896 A MA49896 A MA 49896A MA 49896 A MA49896 A MA 49896A
- Authority
- MA
- Morocco
- Prior art keywords
- insulin analogues
- acylated insulin
- new acylated
- new
- analogues
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
- G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17186612 | 2017-08-17 | ||
| EP17204872 | 2017-12-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA49896A true MA49896A (fr) | 2020-06-24 |
Family
ID=63165388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA049896A MA49896A (fr) | 2017-08-17 | 2018-08-16 | Nouveaux analogues d'insuline acylés et leurs utilisations |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US10919949B2 (fr) |
| EP (1) | EP3668892A1 (fr) |
| JP (2) | JP2020531451A (fr) |
| KR (1) | KR20200038502A (fr) |
| CN (1) | CN111032685A (fr) |
| AU (1) | AU2018317810A1 (fr) |
| BR (1) | BR112020002364A2 (fr) |
| CA (1) | CA3071686A1 (fr) |
| CL (1) | CL2020000310A1 (fr) |
| CO (1) | CO2020002500A2 (fr) |
| IL (1) | IL272394A (fr) |
| MA (1) | MA49896A (fr) |
| MX (1) | MX2020001434A (fr) |
| PE (1) | PE20211264A1 (fr) |
| PH (1) | PH12020550050A1 (fr) |
| RU (1) | RU2020108281A (fr) |
| SG (1) | SG11202001077UA (fr) |
| TW (1) | TW201917134A (fr) |
| WO (1) | WO2019034726A1 (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090074882A1 (en) | 2005-12-28 | 2009-03-19 | Novo Nordisk A/S | Insulin compositions and method of making a composition |
| US10335464B1 (en) | 2018-06-26 | 2019-07-02 | Novo Nordisk A/S | Device for titrating basal insulin |
| CN114096269B (zh) | 2019-07-12 | 2024-06-11 | 诺和诺德股份有限公司 | 高浓度胰岛素制剂 |
| EP4281464A4 (fr) | 2021-01-20 | 2025-01-01 | Viking Therapeutics, Inc. | Compositions et procédés pour le traitement de troubles métaboliques et hépatiques |
| JP7642830B2 (ja) | 2021-09-15 | 2025-03-10 | バイキング・セラピューティクス・インコーポレイテッド | 代謝及び肝臓障害の処置のための組成物及び方法 |
| WO2024185897A1 (fr) * | 2023-03-09 | 2024-09-12 | 学校法人神戸学院 | Étiquette de fragment d'insuline et composition pharmaceutique |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4343898A (en) | 1980-02-11 | 1982-08-10 | Novo Industri A/S | Process for preparing esters of human insulin |
| DK58285D0 (da) | 1984-05-30 | 1985-02-08 | Novo Industri As | Peptider samt fremstilling og anvendelse deraf |
| PH25772A (en) | 1985-08-30 | 1991-10-18 | Novo Industri As | Insulin analogues, process for their preparation |
| US5616729A (en) | 1986-07-17 | 1997-04-01 | Board Of Governors Of Wayne State University | Enhanced chemiluminescence from 1,2-dioxetanes through energy transfer to tethered fluorescers |
| DK105489D0 (da) | 1989-03-03 | 1989-03-03 | Novo Nordisk As | Polypeptid |
| DK155690D0 (da) | 1990-06-28 | 1990-06-28 | Novo Nordisk As | Nye peptider |
| DK10191D0 (da) | 1991-01-22 | 1991-01-22 | Novo Nordisk As | Hidtil ukendte peptider |
| DK33591D0 (fr) | 1991-02-27 | 1991-02-27 | Novo Nordisk As | |
| US6500645B1 (en) | 1994-06-17 | 2002-12-31 | Novo Nordisk A/S | N-terminally extended proteins expressed in yeast |
| ZA954983B (en) | 1994-06-17 | 1996-02-14 | Novo Nordisk As | N-terminally extended proteins expressed in yeast |
| US5693609A (en) | 1994-11-17 | 1997-12-02 | Eli Lilly And Company | Acylated insulin analogs |
| US6451970B1 (en) | 1996-02-21 | 2002-09-17 | Novo Nordisk A/S | Peptide derivatives |
| JP4187796B2 (ja) | 1996-12-20 | 2008-11-26 | ノボ ノルディスク アクティーゼルスカブ | 酵母で発現されたｎ末端伸長タンパク質 |
| ES2180511T3 (es) | 1999-01-26 | 2003-02-16 | Lilly Co Eli | Formulaciones monodispersas de analogos de insulina acilados hexamericos. |
| AU5144400A (en) * | 1999-05-19 | 2000-12-05 | Xencor, Inc. | Novel proteins with insulin-like activity useful in the treatment of diabetes |
| HUP0203475A3 (en) | 1999-12-29 | 2005-11-28 | Novo Nordisk As | Method for making insulin precursors and insulin precursor analogs |
| JP5697831B2 (ja) | 2003-12-03 | 2015-04-08 | ノヴォ ノルディスク アー／エス | 単鎖インシュリン |
| WO2006008238A1 (fr) * | 2004-07-16 | 2006-01-26 | Novo Nordisk A/S | Procede d'acylation selective |
| EP2256130B1 (fr) | 2005-02-02 | 2013-09-25 | Novo Nordisk A/S | Nouveaux dérivés d'insuline |
| DE602007009496D1 (de) | 2006-02-27 | 2010-11-11 | Novo Nordisk As | Insulinderivate |
| EP2404934A1 (fr) | 2006-09-22 | 2012-01-11 | Novo Nordisk A/S | Analogues d'insuline résistants à la protéase |
| KR20100053561A (ko) | 2007-08-15 | 2010-05-20 | 노보 노르디스크 에이/에스 | 아실 및 알킬렌 글리콜 부분을 갖는 인슐린 유사체 |
| ES2618073T3 (es) | 2008-03-14 | 2017-06-20 | Novo Nordisk A/S | Análogos de insulina estabilizados frente a proteasas |
| MX2010009850A (es) * | 2008-03-18 | 2010-09-30 | Novo Nordisk As | Analogos de insulina acilados y etabilizados contra proteasas. |
| CN102245624B (zh) | 2008-12-19 | 2016-08-10 | 印第安纳大学研究及科技有限公司 | 基于酰胺的胰岛素前药 |
| WO2010080606A1 (fr) | 2008-12-19 | 2010-07-15 | Indiana University Research And Technology Corporation | Analogues d'insuline |
| EP2376099A4 (fr) | 2008-12-19 | 2012-04-25 | Univ Indiana Res & Tech Corp | Facteurs de croissance semblables à l'insuline à base d'yl exprimant une haute activité au récepteur de l'insuline |
| US20120241356A1 (en) | 2009-07-06 | 2012-09-27 | Sanofi-Aventis Deutschland Gmbh | Heat- and vibration-stable insulin preparations |
| WO2011159882A2 (fr) | 2010-06-16 | 2011-12-22 | Indiana University Research And Technology Corporation | Nouveaux agonistes stabilisés de l'insuline |
| WO2011159895A2 (fr) | 2010-06-16 | 2011-12-22 | Indiana University Research And Technology Corporation | Agonistes de l'insuline à une seule chaîne très actifs au niveau du récepteur à l'insuline |
| EP2585484A1 (fr) | 2010-06-23 | 2013-05-01 | Novo Nordisk A/S | Analogues de l'insuline contenant des liaisons disulfures supplémentaires |
| US8946147B2 (en) | 2010-06-24 | 2015-02-03 | Indiana University Research And Technology Corporation | Amide-based insulin prodrugs |
| WO2011163460A1 (fr) | 2010-06-24 | 2011-12-29 | Indiana University Research And Technology Corporation | Facteurs de croissance insulinomimétiques à base d'yl à activité élevée sur le récepteur de l'insuline |
| WO2012015692A2 (fr) | 2010-07-28 | 2012-02-02 | Smartcells, Inc. | Polypeptides d'insuline exprimés de façon recombinante et utilisations de ceux-ci |
| EP2627670A2 (fr) | 2010-10-15 | 2013-08-21 | Novo Nordisk A/S | Nouveaux dérivés d'insuline à extrémité n modifiée |
| AR087433A1 (es) | 2011-08-08 | 2014-03-26 | Merck Sharp & Dohme | Analogos de insulina n-glicosilados |
| US9573987B2 (en) | 2011-12-20 | 2017-02-21 | Indiana University Research And Technology Corporation | CTP-based insulin analogs for treatment of diabetes |
| JP2015502971A (ja) | 2011-12-21 | 2015-01-29 | ノヴォ ノルディスク アー／エス | Ｎ末端修飾インスリン誘導体 |
| CN108383902A (zh) | 2012-09-26 | 2018-08-10 | 印第安纳大学研究及科技有限公司 | 胰岛素类似物二聚体 |
| JP6735561B2 (ja) | 2012-12-03 | 2020-08-05 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | Ｏ−グリコシル化カルボキシ末端部分（ｃｔｐ）ペプチド系のインスリンおよびインスリン類似体 |
| WO2014099577A1 (fr) | 2012-12-17 | 2014-06-26 | Merck Sharp & Dohme Corp. | Procédé pour purifier l'insuline et ses analogues |
| WO2014158900A1 (fr) | 2013-03-14 | 2014-10-02 | Indiana University Research And Technology Corporation | Conjugués d'insuline-incrétine |
| CN105392475A (zh) | 2013-07-24 | 2016-03-09 | 诺和诺德股份有限公司 | 包含片剂核和阴离子共聚物涂层的用于口服胰岛素给药的药学组合物 |
| US9884125B2 (en) | 2013-10-04 | 2018-02-06 | Merck Sharp & Dohme Corp. | Glucose-responsive insulin conjugates |
| AR099569A1 (es) * | 2014-02-28 | 2016-08-03 | Novo Nordisk As | Derivados de insulina y los usos médicos de estos |
| EP3197912B1 (fr) | 2014-09-24 | 2023-01-04 | Indiana University Research & Technology Corporation | Promédicaments insuliniques à base d'amide lipidique |
| ES2822994T3 (es) | 2014-09-24 | 2021-05-05 | Univ Indiana Res & Tech Corp | Conjugados de incretina-insulina |
| SG10201809457YA (en) | 2014-11-21 | 2018-11-29 | Merck Sharp & Dohme | Insulin receptor partial agonists |
| US20180000742A1 (en) | 2015-01-29 | 2018-01-04 | Novo Nordisk A/S | Pharmaceutical Composition for Oral Insulin Administration Comprising a Tablet Core and a Polyvinyl Alcohol Coating |
| WO2016144658A1 (fr) | 2015-03-10 | 2016-09-15 | Merck Sharp & Dohme Corp. | Procédé de préparation d'insuline recombinante par microfiltration |
| EP3280450A4 (fr) | 2015-04-08 | 2018-12-12 | Merck Sharp & Dohme Corp. | Conjugués d'insuline sensibles au glucose |
| WO2016172269A2 (fr) | 2015-04-20 | 2016-10-27 | University Of Utah Research Foundation | Analogues d'insuline ayant des peptides à chaîne b raccourcie et procédés associés |
| CA2996455A1 (fr) | 2015-08-25 | 2017-03-02 | Novo Nordisk A/S | Nouveaux derives d'insuline et leurs utilisations medicales |
| WO2017032795A1 (fr) * | 2015-08-25 | 2017-03-02 | Novo Nordisk A/S | Nouveaux dérivés de l'insuline et leurs utilisations médicales |
| EP3341402A1 (fr) * | 2015-08-25 | 2018-07-04 | Novo Nordisk A/S | Nouveaux dérivés de l'insuline et leurs utilisations médicales |
| EP3344651B1 (fr) | 2015-09-02 | 2022-03-02 | Merck Sharp & Dohme Corp. | Procédé d'obtention d'insuline avec liaisons disulfure correctement formées |
-
2018
- 2018-08-16 PE PE2020000179A patent/PE20211264A1/es unknown
- 2018-08-16 US US15/998,755 patent/US10919949B2/en active Active
- 2018-08-16 MX MX2020001434A patent/MX2020001434A/es unknown
- 2018-08-16 TW TW107128618A patent/TW201917134A/zh unknown
- 2018-08-16 MA MA049896A patent/MA49896A/fr unknown
- 2018-08-16 CN CN201880052683.1A patent/CN111032685A/zh not_active Withdrawn
- 2018-08-16 BR BR112020002364-7A patent/BR112020002364A2/pt not_active Application Discontinuation
- 2018-08-16 JP JP2020508562A patent/JP2020531451A/ja not_active Withdrawn
- 2018-08-16 RU RU2020108281A patent/RU2020108281A/ru unknown
- 2018-08-16 EP EP18752779.1A patent/EP3668892A1/fr not_active Withdrawn
- 2018-08-16 SG SG11202001077UA patent/SG11202001077UA/en unknown
- 2018-08-16 WO PCT/EP2018/072191 patent/WO2019034726A1/fr not_active Ceased
- 2018-08-16 KR KR1020207006535A patent/KR20200038502A/ko not_active Withdrawn
- 2018-08-16 CA CA3071686A patent/CA3071686A1/fr not_active Withdrawn
- 2018-08-16 AU AU2018317810A patent/AU2018317810A1/en not_active Withdrawn
-
2020
- 2020-01-31 IL IL272394A patent/IL272394A/en unknown
- 2020-02-05 CL CL2020000310A patent/CL2020000310A1/es unknown
- 2020-02-07 PH PH12020550050A patent/PH12020550050A1/en unknown
- 2020-03-04 CO CONC2020/0002500A patent/CO2020002500A2/es unknown
- 2020-11-05 US US17/089,993 patent/US20210094999A1/en not_active Abandoned
-
2022
- 2022-04-25 JP JP2022071578A patent/JP2022105082A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| RU2020108281A3 (fr) | 2022-03-09 |
| CA3071686A1 (fr) | 2019-02-21 |
| CL2020000310A1 (es) | 2020-07-10 |
| US20190194285A1 (en) | 2019-06-27 |
| IL272394A (en) | 2020-03-31 |
| JP2022105082A (ja) | 2022-07-12 |
| CO2020002500A2 (es) | 2020-06-09 |
| AU2018317810A1 (en) | 2020-03-19 |
| SG11202001077UA (en) | 2020-03-30 |
| US10919949B2 (en) | 2021-02-16 |
| MX2020001434A (es) | 2020-03-20 |
| PE20211264A1 (es) | 2021-07-15 |
| KR20200038502A (ko) | 2020-04-13 |
| BR112020002364A2 (pt) | 2020-09-01 |
| EP3668892A1 (fr) | 2020-06-24 |
| TW201917134A (zh) | 2019-05-01 |
| PH12020550050A1 (en) | 2020-10-19 |
| WO2019034726A1 (fr) | 2019-02-21 |
| RU2020108281A (ru) | 2021-08-26 |
| US20210094999A1 (en) | 2021-04-01 |
| CN111032685A (zh) | 2020-04-17 |
| JP2020531451A (ja) | 2020-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA51288A (fr) | Analogues d'incrétine et leurs utilisations | |
| FR25C1018I2 (fr) | Éthers d'aryle et leurs utilisations | |
| MA49896A (fr) | Nouveaux analogues d'insuline acylés et leurs utilisations | |
| MA51287A (fr) | Analogues d'incrétine et leurs utilisations | |
| MA53652A (fr) | Lipides peg de haute pureté et leurs utilisations | |
| EP2968443A4 (fr) | Analogues d'hepcidine et leurs utilisations | |
| MA50618A (fr) | Polyrhérapies et leurs utilisations | |
| DK3506909T3 (da) | 4'-phosphatanaloger og oligonukleotider omfattende samme | |
| EP3307766A4 (fr) | Protéine d'interleukine-7 modifiée et ses utilisations | |
| EP3397757A4 (fr) | Nouvelles transposases associées à crispr et leurs utilisations | |
| EP3337470A4 (fr) | Conjugués d'aldéhyde et leurs utilisations | |
| MA43551A (fr) | Protéines immunomodulatrices à variants du ligand icos et leurs utilisations | |
| EP3727371A4 (fr) | Inhibiteurs d'hétéromères gpcr et leurs utilisations | |
| EP3359644A4 (fr) | Nouvelles nucléases guidé par l'arn et leurs utilisations | |
| EP3349802A4 (fr) | Dendrimères lipocationiques et leurs utilisations | |
| EP3413816A4 (fr) | Compositions hydratantes et utilisations associées | |
| EP3341404A4 (fr) | Nouveaux analogues d'insuline et leur utilisation | |
| EP3302490A4 (fr) | Inhibiteurs d'autotaxine et leurs utilisations | |
| EP3291676A4 (fr) | Analogues de la mitragynine et leurs utilisations | |
| EP3364958A4 (fr) | Modulateurs d'interaction sestrine-gator2 et leurs utilisations | |
| MA43567A (fr) | Anticorps pacap et leurs utilisations | |
| EP3347020A4 (fr) | Acétamide thiénotriazoldiazépines et leurs utilisations | |
| EP3436434A4 (fr) | Analogues d'indoline et leurs utilisations | |
| EP3347021A4 (fr) | Cyano-thiénotriazoloazépines et leurs utilisations | |
| EP3351533A4 (fr) | Dérivé biaryle et médicament le contenant |